PUBLIC COMPANY
savePATH
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagRecall10 co-mentions · 10 sources
- tagHematology6 co-mentions · 6 sources
- tagAdCom4 co-mentions · 4 sources
- tag510(k) Clearance3 co-mentions · 3 sources
- companyUniversity of Virginia1 co-mentions · 1 sources
- companyUniversity of Washington1 co-mentions · 1 sources
- tagCardiology1 co-mentions · 1 sources
- tagImmunology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
8
approvals ytd
0
recalls ytd
6
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
- phase2Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
- phase2Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
- phase2Infant Malaria Vaccine Schedule Optimization
- phase3Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
- phase1Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
- phase2Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
🐶 Hiring Signal
News
- Ultragenyx, after setbacks, nabs first gene therapy approvalThe clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.biopharma_dive · 12h ago
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 14h ago
- Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decisionThe accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently revi…biospace · 15h ago
- Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureInvestors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.biospace · 15h ago
- STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejectionCapricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.stat · 16h ago
- Why pediatric rare oncology outperforms in a volatile biotech marketReal progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investm…biospace · 23h ago
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Trump picks White House aide Heidi Overton as FDA chief: ReportsIf Heidi Overton clears the Senate nomination process, analysts say she will have a tough job ahead to “restore predictability” to an agency battered by layoffs and controversial policies.biospace · 1d ago
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreAmylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; p…biospace · 1d ago
- Opinion: AI has created a shadow medical systemFinancial incentives – health care makes up nearly one-fifth of the American economy – have driven every major AI company into health care.stat · 1d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that